Hospital Pharmacy presents this feature to keep pharmacists abreast of new publications in the medical/pharmacy literature. Articles of interest regarding a broad scope of topics are abstracted monthly. Suggestions or comments may be addressed to Flint Russett, St. Claire Regional Medical Center, 222 Medical Circle, Morehead, KY 40351, or e-mail: FSRussett@st-claire.org.
SmytheM.A.MehtaT.P.KoerberJ.M.Development and implementation of a comprehensive heparin-induced thrombocytopenia recognition and management protocol. Am J Health Syst Pharm.2012; 69(3): 241–248.
4.
TurkogluM.DizbayM.ÇiftçiA.Colistin therapy in critically ill patients with chronic renal failure and its effect on development of renal dysfunction. Int J Antimicrob Agents.2012; 39(2): 142–145.
5.
VrijensB.De GeestS.HughesD.A.; for the ABC project team. A new taxonomy for describing and defining adherence to medications [published online ahead of print January 16, 2012]. Br J Clin Pharmacol.
6.
WestanmoA.WuX.CarmichaelJ.M.DennisS.J.Improvement of competence after preparation for board certification examination. Am J Health Syst Pharm.2012; 69(3): 186–190.
AyadA.E.MasryA.E.Epidural steroid and Clonidine for chronic intractable post-thoracotomy pain: a pilot study. Pain Pract.2012; 12(1): 7–13.
9.
BurkeJ.P.SanchezR.J.JoshiA.V.Health care costs in patients with fibromyalgia on Pregabalin vs. Duloxetine. Pain Pract.2012; 12(1): 14–22.
10.
KulshreshthaP.GuptaR.YadavR.K.Effect of low-dose amitriptyline on autonomic functions and peripheral blood flow in fibromyalgia: a pilot study. Pain Med.2012; 13(1): 131–136.
11.
YaoP.MengL.X.MaJ.M.Sustained-release oxycodone tablets for moderate to severe painful diabetic peripheral neuropathy: a multicenter, open-labeled, postmarketing clinical observation. Pain Med.2012; 13(1): 107–114.
12.
AngiolilloD.J.FirstenbergM.S.PriceM.J.; for the BRIDGE Investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA.2012; 307(3): 265–274.
13.
ChinJ.H.LeeE.H.SonH.J.Preoperative treatment with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker has no beneficial effect on the development of new-onset atrial fibrillation after off-pump coronary artery bypass graft surgery. Clin Cardiol.2012; 35(1): 37–42.
14.
GoyalA.SpertusJ.A.GoschK.Serum potassium levels and mortality in acute myocardial infarction. JAMA.2012; 307(2): 157–164.
15.
SchmidtM.JohansenM.B.MaengM.Concomitant use of Clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation. [published online ahead of print January 13, 2012]. Br J Clin Pharmacol.
16.
BennettW.L.OdelolaO.A.WilsonL.M.Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: a systematic review [published online ahead of print January 3, 2012]. Ann Intern Med.
17.
Goldman-LevineJ.D.Beyond metformin: initiating combination therapy in patients with type 2 diabetes mellitus. Pharmacotherapy.2011; 31(12S): 44S–53S.
18.
LeeP.ChangA.BlaumC.Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis. J Am Geriatr Soc.2012; 60(1): 51–59.
19.
QuinzlerR.UdeM.FranzmannA.Treatment duration (persistence) of basal insulin supported oral therapy (BOT) in type-2 diabetic patients: comparison of insulin glargine with NPH insulin. Int J Clin Pharmacol Ther.2012; 50(1): 24–32.
20.
TzefosM.HarrisK.BrackettA.Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults. Ann Pharmacother.2012; 46(1): 68–78.
21.
ButterfieldJ.M.LawrenceK.R.ReismanA.Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of phase III and IV randomized clinical trial data. J Antimicrob Chemother.2012; 67(2): 494–502.
22.
GruberV.A.RaineyP.M.MoodyD.E.Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir. Clin Infect Dis.2012; 54(3): 414–423.
23.
PergolizziJ.V.JrLabhsetwarS.A.PuenpatomR.A.Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids. Pain Pract.2012; 12(1): 33–44.
24.
PergolizziJ.V.JrLabhsetwarS.A.PuenpatomR.A.Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioids. Pain Pract.2012; 12(1): 45–56.
25.
ClarkeG.CryanJ.F.DinanT.G.QuigleyE.M.Review article: probiotics for the treatment of irritable bowel syndrome – focus on lactic acid bacteria. Aliment Pharmacol Ther.2012; 35(4): 403–413.
26.
LiH.Y.LiB.WeiY.G.Higher tacrolimus blood concentration is related to hyperlipidemia in living donor liver transplantation recipients. Dig Dis Sci.2012; 57(1): 204–209.
27.
RostholderE.AhmedA.CheifetzA.S.MossA.C.Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis [published online ahead of print January 13, 2012]. Aliment Pharmacol Ther.
28.
SacharD.B.Management of acute, severe ulcerative colitis. J Dig Dis.2012; 13(2): 65–68.
HeinrichL.S.TokumaruS.ClarkN.M.Development and implementation of a piperacillin-tazobactam extended infusion guideline. J Pharm Pract.2011; 24(6): 571–576.
31.
KarageorgopoulosD.E.WangR.YuX.H.FalagasM.E.Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in gram-negative pathogens. J Antimicrob Chemother.2012; 67(2): 255–268.
32.
LewisR.E.Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infections. Am J Ther.2012; 19(1): 51–63.
33.
SnydmanD.R.Empiric antibiotic selection strategies for healthcare-associated pneumonia, intra-abdominal infections, and catheter-associated bacteremia. J Hosp Med.2012; 7(S1): S2–S12.
34.
SpellbergB.LipskyB.A.Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis.2012; 54(3): 393–407.
35.
BrahmN.C.WashingtonN.B.Increased patient response to in-tramuscular haloperidol decanoate following a change in needle length. J Pharm Pract.2011; 24(6): 561–563.
36.
CraftS.BakerL.D.MontineT.J.Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol.2012; 69(1): 29–38.
37.
DelantyN.JonesJ.TonnerF.Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. Epilepsia.2012; 53(1): 111–119.
38.
FriedmanJ.H.Atypical antipsychotic drugs in the treatment of Parkinson's disease. J Pharm Tract.2011; 24(6): 534–540.
39.
GunthorpeM.J.LargeC.H.SankarR.The mechanism of action of retigabine (ezogabine), a first-in-class K+channel opener for the treatment of epilepsy [published online ahead of print January 5, 2012]. Epilepsia.
40.
KrymchantowskiA.V.da Cunha JevouxC.BigalM.E.Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders. J Headache Fain.2012; 13(1): 53–59.
41.
PhelanE.A.BorsonS.GrothausL.Association of incident dementia with hospitalizations. JAMA.2012; 307(2): 165–172.
42.
CaudleK.E.IngerA.G.ButlerD.R.RogersP.D.Echinocandin use in the neonatal intensive care unit. Ann Pharmacother.2012; 46(1): 108–116.
43.
FeudtnerC.DaiD.HexemK.R.Prevalence of polypharmacy exposure among hospitalized children in the United States. Arch Pediatr Adolesc Med.2012; 166(1): 9–16.
44.
HassallE.Over-prescription of acid-suppressing medications in infants: how it came about, why it's wrong, and what to do about it. J Pediatr.2012; 160(2): 193–198.
45.
TerrisM.CreanP.Fluid and electrolyte balance in children. Anaesth Intensive Care Med.2012; 13(1): 15–19.
